TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02654223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group
Study: NCT03787043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC(MP-513 10mg/Metformin XR 750mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC(MP-513 10mg/Metformin XR 750mg)
Study: NCT01643980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone
Description: 200 mg vaginal route per day
Study: NCT02654223

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual placebo
Description: Comparison between placebo and active group
Study: NCT00929240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
Study: NCT01643980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical pessary
Description: Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
Study: NCT00663442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Description: 18, 36, 54 mg
Study: NCT00385450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir/placebo
Description: 1250mg/twice each day/four days.
Study: NCT01933087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene promotion
Description: The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
Study: NCT01422330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
Study: NCT02991690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification \[510(k), K030421\]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
Study: NCT00424853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin followed by gemcitabine
Description: docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
Study: NCT01574534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon
Description: PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting stent
Description: PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
Study: NCT04522492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy
Description: 2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life promotion
Description: 2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
Study: NCT02086019

Intervention type: DRUG
Group type: OTHER
Intervention: Conservative Arm
Description: crossover to angiogram only if predefined criteria met

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Invasive Arm
Description: angiogram with PCI or CABG revascularisation if appropriate
Study: NCT01892488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Description: Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD
Study: NCT03496701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lens
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control lens
Description: contact lens
Study: NCT02633176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m\^2 intravenously on day 1,then 250 mg/m\^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m\^2 intravenously every week concurrent with radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
Study: NCT02278913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Bolus (Glargine and Glulisine)
Description: Glargine daily + Glulisine before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin
Description: NPH twice a day + Regular insulin before meals
Study: NCT01264939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Study: NCT01722695

Intervention type: OTHER
Group type: OTHER
Intervention: Dialyzer comparison
Description: Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization.
Study: NCT01264939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
Description: Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
Study: NCT04078022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a strain 2457T Challenge Agent
Description: Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a strain 2457T Challenge Agent
Description: Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a strain 2457T Challenge Agent
Description: Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
Study: NCT01264939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
Description: Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
Study: NCT04348851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver problem-solving
Description: Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
Study: NCT00424853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin followed by gemcitabine
Description: docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
Study: NCT01576055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGRIS Vascular Stent
Description: Implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARD LifeStent
Description: Implant
Study: NCT03048032

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.

Intervention type: PROCEDURE
Intervention: Echocardiography exam
Description: A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.

Intervention type: PROCEDURE
Intervention: Echocardiography exam
Description: A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
Study: NCT01495182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber
Description: A proprietary fiber will be given to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Description: A proprietary fiber will be given to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Description: A proprietary fiber will be given to subjects
Study: NCT04348851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver problem-solving
Description: Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
Study: NCT03557021

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV Drug resistance testing
Description: HIV Drug resistance testing by HIV pro DNA sanger sequencing
Study: NCT03113422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Venetoclax
Description: 1 cycle = 28 days.~* Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~* Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~* Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance Venetoclax
Description: Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
Study: NCT00326690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Egg Device
Study: NCT03557021

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV Drug resistance testing
Description: HIV Drug resistance testing by HIV pro DNA sanger sequencing
Study: NCT03534037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Description: Febuxostat 40 mg orally per day plus dietary control only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzbromarone 50mg
Description: Benzbromarone 50mg orally per day plus dietary control only

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Dietary control only
Study: NCT06379334

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine test
Description: Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine test
Description: Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine test
Description: Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine test
Description: Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
Study: NCT03623230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Femoral Nerve Block
Description: Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator
Study: NCT00363961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: resistance exercise vs sham comparison

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance exercise
Description: resistance exercise vs sham comparison
Study: NCT00058461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03709563

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutraceutical Supplement
Description: Standardized Botanicals. Take 4 capsules by mouth daily with a meal
Study: NCT03623230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Femoral Nerve Block
Description: Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dressing
Description: Only dressing will be applied to related area to protect blindness between groups
Study: NCT03709563

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Take 4 capsules by mouth daily with a meal
Study: NCT01955616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Study: NCT03623230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Perineural Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.125% Injectable Solution
Description: Perineural Injection